<DOC>
	<DOCNO>NCT00775814</DOCNO>
	<brief_summary>The purpose study determine efficacy candesartan , daily ( QD ) , combine hydrochlorothiazide lower blood pressure insulin-resistant , obese patient hypertension .</brief_summary>
	<brief_title>Efficacy Candesartan Reducing Blood Pressure Insulin-Resistant , Obese Patients With Hypertension .</brief_title>
	<detailed_description>Abdominal obesity major risk factor insulin resistance development type 2 diabetes . It associate sodium retention , leave ventricular hypertrophy elevate marker inflammation important predictor cardiovascular morbidity mortality . Activation sympathetic nervous system renin angiotensin aldosterone system involve development hypertension obese individual . Hypertension obese individual often associate dyslipidemia , hyperinsulinaemia impair glucose tolerance . In order decrease cardiovascular risk obese hypertensive patient , therapy direct lower blood pressure value also improvement metabolic situation . As possible antihypertensive treatment base angiotensin receptor antagonist ( like candesartan ) might superior beta-blocker calcium channel blocker therapy prevent diabetes , combination candesartan already exist insufficiently effective beta-blocker calcium channel blocker therapy use study .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Has Abdominal obesity waist circumference great 102 cm ( men ) great 88 cm ( woman ) . Has body mass index great 30 kg/m^2 . Has hypertension adequately control ( seat diastolic blood pressure great 95 mmHg less equal 110 mmHg median value three reading ) monotherapy either betablocker calcium channel blocker . Has Homeostasis Model Assessment Insulin Resistance index great 3.99 . Has hyperlipidemia fasting level total cholesterol great 250 mg/dL ( 6.45 mmol/L ) lowdensity lipoprotein cholesterol great 160 mg/dL ( 4.13 mmol/L ) triglycerides great 250 mg/dL ( 2.82 mmol/L ) . Existing Hydrochlorothiazide therapy start study . Diabetes mellitus type 1 2 [ know newly detect ( Screening : fasting plasma glucose great 7.0 mmol/L ) ] . Chronic renal impairment Screatinine great equal 1.8 mg/dL . Presence single kidney state kidney transplantation know bilateral renal artery stenosis interventional treatment renal artery stenosis last year . Hyperkalemia ( potassium great 5.5 mmol/L ) . Known electrolyte imbalance , e.g . hypocalcaemia hypokalemia resistant treatment . Nephrotic syndrome . Thyroid dysfunction . Primary secondary hyperaldosteronism . Cushing syndrome . Known suspected familial hypercholesterolemia . Severe hepatic impairment ( cholestasis ( bilirubin great 2.0 mg/dL ) alanine aminotransferase and/or aspartate aminotransferase great 3 time upper limit normal and/or Î³glutamyl transpeptidase great 5 time upper limit normal ) . History chronic heart failure . History overt coronary heart disease . History silent myocardial infarction . Hemodynamically relevant stenosis mitral and/or aortic valve . History stroke . Stage 3 hypertension ( systolic blood pressure great 180 mmHg diastolic blood pressure great 110 mmHg ) . Angiotensin convert enzyme inhibitor angiotensin receptor blocker therapy previous 4 week . Lipidlowering therapy cholesterol synthesis enzyme inhibitor anticipate initiation therapy . History autoimmune disease . History cancer last 5 year waste disease . Intake prohibit concomitant medication . Has know hypersensitivity/allergy study drug . Has drug addiction and/or extensive use alcohol . Psychological and/or emotional problem would render informed consent invalid limit ability patient comply study requirement . Participation clinical investigation within 30 day prior enrolment trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Blood Pressure</keyword>
	<keyword>Insulin , Resistant</keyword>
</DOC>